COVID 19. Corona virus infection, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Patients in the itervetion group will receive the drug of this study after treatment with routine medications of the disease, which is 14 mg ivermectin tablet, so t
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age =18 years Laboratory polymerase chain reaction (PCR) confirmed infection with COVID19 Hospitalized Satisfaction to participate in the study Acceptance of non-participation in another study before the 28th day of the study
Exclusion criteria
Exclusion criteria: Patients with a history of allergic reaction to Ivermectin Renal dysfunction Liver dysfunction Pregnancy or deciding to get pregnant or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Viral diagnostic test. Timepoint: The first day of the study. Method of measurement: Polymerase chain reaction.;Duration of hospitalization. Timepoint: Time of dyscharge. Method of measurement: Patient file. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fever. Timepoint: Daily. Method of measurement: Thermometer.;Respiratory rate. Timepoint: Daily. Method of measurement: Patient file.;Dyspnea. Timepoint: Daily. Method of measurement: Patients interview and patient file.;Cough. Timepoint: Daily. Method of measurement: Patients interview and patient file.;Cell blood count. Timepoint: The first day of the study and the end of the study. Method of measurement: Lab test.;C_reactive protein. Timepoint: The first day of the study and the end of the study. Method of measurement: Lab test.;CT scan. Timepoint: The first day of the study and the end of the study. Method of measurement: CT scan set. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMehran Varnasseri
Ahvaz University of Medical Sciences
Outcome results
None listed